TOP TIERMARKET NEWSWIRE

News & sentiment

AURINIA PHARMACEUTIC Equity (AUPH) — News & AI sentiment

AURINIA PHARMACEUTIC Equity (AUPH) news roundup. 1 story in the past week, 4 over 30 days. Average 30-day sentiment is 58.8/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 2 sales totalling $546K — net selling of $546K. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

1

avg sentiment 63/100

30d stories

4

avg sentiment 58.8/100

Insider net (90d)

$546K

0 buys · 2 sells

Congress (90d)

0

0 buys · 0 sells

AUPH news in the last 24 hours, 7 days, 30 days and 90 days

How much AUPH coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	AUPH stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	1	63/100	AUPH headlines →
Last 30 days	4	58.8/100	AUPH headlines →
Last 90 days	21	58.3/100	AUPH headlines →

Latest stories on AUPH

Aurinia’s (AUPH) Profits Surge While Its One Drug Just Got Company

Yahoo Top63 · neutralearnings

5d ago

AUPH Trading Strategies for Aurinia Pharm Ord Stock

Barchart50 · neutralgeneral

Sep 11

Immatics and 4 More Stocks See Activist Action

Barron's55 · neutralgeneral

Sep 4

Could Aurinia Pharmaceuticals (AUPH) Stock Win Big After its LUPKYNIS Patent Settlement With Teva Pharmaceuticals (TEVA)?

Yahoo Finance67 · bullishgeneral

Aug 28

Aurinia Shares Gains After Settling Patent Lawsuit With Teva

MarketWatch56 · neutralgeneral

Aug 20

Aurinia’s Patent Settlement with Teva Secures Voclosporin Exclusivity Until 2036 August 20, 2026

MarketChameleon67 · bullishgeneral

Aug 20

AUPH Stock Rallies 6% After-Hours — Here’s Why

Stocktwits News67 · bullishgeneral

Aug 19

Aurinia settles Lupkynis patent litigation with Teva

Seeking Alpha56 · neutralgeneral

Aug 19

Aurinia Settles Patent Infringement Lawsuit With Teva

MarketWatch56 · neutralgeneral

Aug 19

Aurinia stock falls on Teva patent settlement for voclosporin

Investing.com Markets34 · bearishgeneral

Aug 19

Aurinia Pharmaceuticals Inc. (AUPH) files 8-K

SEC 8-K50 · neutralgeneral

Aug 19

Aurinia Settles Patent Litigation with Teva

StockTitan56 · neutralgeneral

Aug 19

Aurinia Pharmaceuticals Doubles Down On Its Pipeline

Seeking Alpha56 · neutralproduct/pr

Aug 12

Aurinia Pharmaceuticals price target raised to $16 from $15 at RBC Capital

The Fly61 · neutralanalyst

Aug 7

Aurinia Posts Strong Q2 2026 Results on Rising LUPKYNIS Sales

TipRanks71 · bullishearnings

Aug 6

Aurinia Posts Strong Q2 Results, Reaffirms 2026 Outlook and Advances Autoimmune Pipeline

TipRanks68 · bullishearnings

Aug 6

Aurinia Pharmaceuticals Reports 74% Net Income Growth and Initiates New Lupus Nephritis Study—Is the Pace Sustainable? August 6, 2026

MarketChameleon73 · bullishproduct/pr

Aug 6

Aurinia Pharmaceuticals Inc. (AUPH) files 8-K

SEC 8-K50 · neutralgeneral

Aug 6

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

StockTitan56 · neutralearnings

Aug 6

Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis | AUPH Stock News

StockTitan56 · neutralproduct/pr

Jul 6

Is Aurinia Pharmaceuticals Inc. (AUPH) A Good Stock To Buy Now?

Yahoo Top57 · neutralanalyst

Jun 29

Aurinia Pharmaceuticals and Four More Stocks See Activist Action

Barron's50 · neutralgeneral

Jun 12

Aurinia’s PRESERVE Trial: New Combination Strategy for Lupus Nephritis in Focus

TipRanks56 · neutralproduct/pr

Jun 12

Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million

The Motley Fool63 · neutralgeneral

Jun 7

Tang Capital Boosts Stake in Aurinia Pharmaceuticals—Owns 10% After $3.1 Million Stock Purchase

MarketChameleon63 · neutralgeneral

Jun 5

Open AUPH in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →